Baxalta Inc., the biopharma company that will separate from Baxter in mid-2015, will be headquartered in Bannockburn, IL. The lease agreement for the approximately 260,000 sq.-ft. facility extends more than 10 years.   Upon completion of the separation, Baxalta will have approximately $6 billion in global revenues and will continue its efforts to provide therapeutic treatments for people with rare conditions, chronic diseases or limited treatment options. Supported by advanced technical and manu...